Albany, NY -- (SBWIRE) -- 09/30/2016 -- The global mycoses market is expected to witness good growth in the coming years. As the number of fungal infections grows, the demand for therapies to treat these conditions will grow. Mycoses are fungal skin infections that are caused by fungi. These fungi are primarily from groups such as yeasts, dermatophytes, and molds.

The primary growth driver for the global mycoses market is the accelerating number of fungal infections. Here are some facts from the National Library of Medicine, which illustrate the prevalence of mycoses.

Mycosis fungoides affects 1 individual in every 100,000 to 350,000
It contributed to around 70% of cutaneous T-cell lymphomas
This condition affects males more than females
In the U.S., there exist around 3.6 cases that are affected with this mycosis per million people
Mycoses tends to affect the patients of HIV/AIDS

Download free exclusive Brochure of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3112

North America to Lead the Global Mycoses Market

The global mycoses market is dominated by North America. This regional market is experiencing an increasing prevalence of HIV/AIDS, which will drive the mycoses market in the coming few years. Additionally, rising awareness of mycoses among individuals in the North America mycoses market will further fuel this regional market.

Asia Pacific to be a Promising Market

Asia Pacific is also expected to demonstrate good growth in the coming few years in the global mycoses market. Some of the market drivers for this region include the rising prevalence of mycoses in this region and the presence of a large population base. Furthermore, as mycoses affects individuals with compromised immune systems, the growing number of diabetes patients in Asia Pacific will prove favorable for this mycoses market. Elevated tax benefits, along with favorable reimbursement policies in this region, will also contribute to this regional mycoses market's growth.

Demand for Mycoses Therapies to Escalate

On the basis of treatment, the global mycoses market is divided into photodynamic therapy, radiation therapy, chemotherapy, targeted therapy, and drug medication. The global antifungal market is presently worth more than US$5 billion and is experiencing consistent annual growth. The mycoses therapies sector within the global antifungal market is projected to witness good growth in the foreseeable future.

Furthermore, fungi are currently recognized as a major issue in several respiratory conditions, as they are responsible for exacerbation of the symptoms in COPD, bronchiectasis, and asthma patients. This trend is expected to elevate the use of antifungal drugs in the coming years.

Peak Sales for Drugs Counteracted by Emergence of Resistant Fungal Strains

Moreover, one of the drug medications used to treat mycoses – fluconazole – is an established agent. Recently, this agent experienced record-breaking sales in excess of US$1 billion. Similarly, many other antifungal drugs experienced peak sales recently. The global mycoses market will be driven by many such factors. However, one factor that is suppressing the growth of the market is the increasing resistance of fungi to antifungal drugs.

Players in the global mycoses market are involved in developing novel therapeutics that will help treat mycoses effectively. Some of the firms focused on developing novel therapeutics in the global mycoses market are Xel Pharmaceuticals, Quinnova Pharmaceuticals, Pacgen Biopharmaceuticals Corporation, Novabiotics, Moberg Derma, Nuvo Research, Pfizer, Merck & Co., Helix BioMedix, and Bayer AG.